Skip to main content
Addgene

L1
(Plasmid #21200)

Full plasmid sequence is not available for this item.

Loading...

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 21200 Standard format: Plasmid sent in bacteria as agar stab 1 $85

Backbone

  • Vector backbone
    LZRS-RfA
  • Backbone size w/o insert (bp) 11100
  • Vector type
    Retroviral
  • Selectable markers
    Puromycin

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    Stbl3
  • Growth instructions
    STBL2
  • Copy number
    Low Copy

Gene/Insert

  • Gene/Insert name
    Mek2
  • Alt name
    MAP2K2
  • Alt name
    ER-{alpha}
  • Alt name
    Esr1
  • Species
    H. sapiens (human), M. musculus (mouse)
  • Insert Size (bp)
    2200
  • Mutation
    Mek2 K101A fused to ER*, catalytically inactive
  • Entrez Gene
    Esr1 (a.k.a. ER, ER-alpha, ERa, ERalpha, ESR, Estr, Estra, Nr3a1)
  • Entrez Gene
    MAP2K2 (a.k.a. CFC4, MAPKK2, MEK2, MKK2, PRKMK2)

Cloning Information

  • Cloning method Gateway Cloning
  • 5′ cloning site attR (not destroyed)
  • 3′ cloning site attR (not destroyed)
  • 5′ sequencing primer TGGATACACGCCGCCCACGTG
  • 3′ sequencing primer ATCGTCGACCACTGTGCTGG
  • (Common Sequencing Primers)

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    L1 was a gift from Paul Khavari (Addgene plasmid # 21200 ; http://n2t.net/addgene:21200 ; RRID:Addgene_21200)
  • For your References section:

    Mek1 alters epidermal growth and differentiation. Scholl FA, Dumesic PA, Khavari PA. Cancer Res. 2004 Sep 1;64(17):6035-40 10.1158/0008-5472.CAN-04-0017 PubMed 15342384